Home » Stocks » SPRO

Spero Therapeutics, Inc. (SPRO)

Stock Price: $17.91 USD -0.90 (-4.78%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
Market Cap 492.67M
Revenue (ttm) 11.05M
Net Income (ttm) -84.68M
Shares Out 21.93M
EPS (ttm) -4.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $17.91
Previous Close $18.81
Change ($) -0.90
Change (%) -4.78%
Day's Open 18.62
Day's Range 17.80 - 18.70
Day's Volume 111,062
52-Week Range 5.25 - 23.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

Zacks Investment Research - 1 month ago

Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

Seeking Alpha - 1 month ago

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Sp...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

Seeking Alpha - 3 months ago

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme...

Insider Monkey - 4 months ago

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...

Other stocks mentioned: BPMC, ANAB, DRNA, QURE
GlobeNewsWire - 4 months ago

15 data presentations cover each of Spero's three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Sper...

Zacks Investment Research - 5 months ago

Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and co...

The Motley Fool - 5 months ago

The pricing of a stock offering is causing the drugmaker's shares to fall.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and co...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and co...

GlobeNewsWire - 5 months ago

Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract inf...

Zacks Investment Research - 6 months ago

The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comm...

Seeking Alpha - 6 months ago

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 27.35% and -41.46%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 6 months ago

Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20  

Zacks Investment Research - 7 months ago

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. (SPRO).

Seeking Alpha - 9 months ago

Spero Therapeutics, Inc. (SPRO) CEO Dr.

Zacks Investment Research - 9 months ago

Spero Therapeutics Inc (SPRO) delivered earnings and revenue surprises of 9.63% and -49.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 9 months ago

Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020

GlobeNewsWire - 9 months ago

ADAPT-PO topline results expected in the third quarter of 2020 ADAPT-PO topline results expected in the third quarter of 2020

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and co...

GlobeNewsWire - 10 months ago

Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson Spero brings significant ...

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and co...

Zacks Investment Research - 11 months ago

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019.

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

Zacks Investment Research - 11 months ago

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

GlobeNewsWire - 1 year ago

$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 $30 Million fully backstopped rights offering will be available to all stockh...

Zacks Investment Research - 1 year ago

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

GlobeNewsWire - 1 year ago

First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of ...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and com...

Seeking Alpha - 1 year ago

Infectiously Challenging - Spero's Exciting Progress

Zacks Investment Research - 1 year ago

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -18.75% and 128.83%, respectively, for the quarter ended September 2019.

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmona... [Read more...]

Industry
Biotechnology
IPO Date
Nov 2, 2017
CEO
Ankit Mahadevia
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
SPRO
Full Company Profile

Financial Performance

In 2019, SPRO's revenue was $18.15 million, an increase of 357.56% compared to the previous year's $3.97 million. Losses were -$60.93 million, 46.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is 32.88, which is an increase of 83.58% from the latest price.

Price Target
$32.88
(83.58% upside)
Analyst Consensus: Strong Buy